目的 观察白蛋白结合型紫杉醇二线治疗晚期三阴性乳腺癌的效果及安全性. 方法 回顾2011年2月—2014年10月接受白蛋白结合型紫杉醇二线治疗的晚期三阴性乳腺癌21例的临床资料. 治疗方法为白蛋白结合型紫杉醇125 mg/m2 静脉滴注 (第1天和第8天) ,21 d为1个周期,每周期评价毒性及不良反应,每2个周期评价疗效,随访患者的生存状况,直至疾病进展或出现无法耐受的不良反应. 结果 21例共完成109个周期的化疗,平均5. 4个周期. 21例中位随访时间6. 9个月,均可评价疗效. 本组部分缓解3例,稳定14例,疾病进展4例,总有效率14. 3%,疾病控制率66. 7%,中位无进展生存期4. 7个月,中位总生存期6. 9个月,无治疗相关性死亡. 毒性及不良反应主要为中性粒细胞减少7例(33. 3%),血小板减少3例(14. 3%),血红蛋白减少2例(9. 5%),粒细胞缺乏性发热1例(4. 8%). 结论 白蛋白结合型紫杉醇二线治疗晚期三阴性乳腺癌效果较好,不良反应可耐受.%Objective To evaluate the efficacy and safety of Albumin-bound paclitaxel as second-line treatment in ad-vanced triple negative breast cancer ( TNBC) . Methods Clinical data of 21 patients with advanced TNBC under going Albumin-bound paclitaxel as second-line chemotherapy during February 2011 and October 2014 were analyzed. Albumin-bound paclitaxel was given via intravenous drip at 125 mg/m2(on the first day and eighth day), and a cycle was 21 days. The adverse reactions were e-valuated every cycle until progression of disease or intolerable adverse reaction occurred. The short-term response was evaluated ev-ery two cycles. The patients were followed-up, and the survival condition was analyzed. Results 21 patients completed 109 cycles of chemotherapy, with an average of 5. 4 cycles. All the patients were evaluable for treatment response. The median follow-up time was 6. 9 months. There were 3 cases of partial response;14 cases of stable disease and 4 of progressive disease. The rate of RR was 14. 3%, DCR was 66. 7%. The median PFS was 4. 7 months, and the median OS was 6. 9 months. There was no treatment-related death. The major side effects were myelosuppression. There were 7 cases of neutropenia (33. 3%), 3 cases of thrombocytopenia (14. 3%), 2 cases of anemia (9. 5%), 1 case of lack of granulocyte fever (4. 8%). Conclusion Albumin-bound paclitaxel as second-line chemotherapy treatment in advanced TNBC is effective with good tolerance for adverse reactions.
展开▼
